1. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2–positive breast cancer cells in a synergistic manner
- Author
-
Jean-François Laes, Françoise Bex, Christos Sotiriou, Christine Desmedt, Arsène Burny, Fatima Cardoso, Virginie Durbecq, Bassam Badran, Karen Willard-Gallo, Martine Piccart, Laurence Lagneaux, and Jeffrey S. Ross
- Subjects
Cancer Research ,Receptor, ErbB-2 ,Phases of clinical research ,Apoptosis ,Breast Neoplasms ,Pharmacology ,Antibodies, Monoclonal, Humanized ,Bortezomib ,Breast cancer ,Trastuzumab ,Cell Line, Tumor ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,skin and connective tissue diseases ,Cell Nucleus ,Chemistry ,NF-kappa B ,Antibodies, Monoclonal ,Cancer ,Drug Synergism ,medicine.disease ,Boronic Acids ,Metastatic breast cancer ,Oncology ,Drug Resistance, Neoplasm ,Pyrazines ,Proteasome inhibitor ,Cyclin-Dependent Kinase Inhibitor p27 ,medicine.drug - Abstract
Background: Preclinical and clinical studies have shown that the proteasome inhibitor bortezomib (PS341, Velcade) is highly effective when combined with chemotherapeutic agents. The value of trastuzumab (Herceptin) in HER-2–positive (3+ score by immunohistochemistry or fluorescence in situ hybridization positive) breast cancer is also known; however, the response rate is
- Published
- 2006
- Full Text
- View/download PDF